Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical obtained clinical trial approval for the IM-101 injection from China's National Medical Products Administration.
The drug candidate has been developed for the treatment of chronic hepatitis B, according to a Thursday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.